EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

NCT06390059 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DEVICE: Tumor Treating Fields
DRUG: Atezolizumab
DRUG: Gemcitabine
DRUG: nab-paclitaxel

Sponsor

NovoCure Ltd.